Innovative Diagnostic Pipeline
Adding new pages to the story of the adaptive immune system
At Adaptive, we’re investing in the continued development of immune-driven medicine products, which add new meaning to the stories every patient’s immune system has to tell.
clonoSEQ has been cleared by the FDA for the detection and monitoring of MRD (minimal residual disease) in bone marrow samples from multiple myeloma and B-cell acute lymphoblastic leukemia (ALL) patients. clonoSEQ is also available for use in other lymphoid cancers as a laboratory developed test (LDT). We intend to file to expand the clonoSEQ FDA label to multiple additional indications, starting with chronic lymphocytic leukemia (CLL) in 2019, followed by non-Hodgkin’s lymphomas (NHL). We are also generating data for submission to validate the use of clonoSEQ to monitor MRD from blood samples.
By combining Adaptive’s immune sequencing and mapping technologies with Microsoft’s large-scale machine learning and cloud computing capabilities, we are creating a map of the interaction between the immune system and disease, the TCR-Antigen Map. This will inform the development of a diagnostic test that may enable early detection of many diseases from a single blood test.
For a decade, we have been studying and quantifying the properties of a robust, healthy adaptive immune system. Now, we are applying these measurable properties in the context of clinical trials across disease states, including transplantation and immunotherapy, to assess whether the presence of a diverse immune repertoire in a patient’s blood can inform prognosis or predict responses in the clinic. We are also assessing the clinical relevance of a focused and robust immune response within tumor tissue prior to treatment to predict and monitor response to immunotherapy.